| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ... Nature genetics 27 (4), 383-391, 2001 | 2706 | 2001 |
| Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America SK Gupta, JA Eustace, JA Winston, II Boydstun, TS Ahuja, RA Rodriguez, ... Clinical Infectious Diseases 40 (11), 1559-1585, 2005 | 790 | 2005 |
| The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate … BA Ward, JC Gorski, DR Jones, SD Hall, DA Flockhart, Z Desta Journal of Pharmacology and Experimental Therapeutics 306 (1), 287-300, 2003 | 712 | 2003 |
| Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity N Chalasani, H Aljadhey, J Kesterson, MD Murray, SD Hall Gastroenterology 126 (5), 1287-1292, 2004 | 623 | 2004 |
| Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7 JA Williams, BJ Ring, VE Cantrell, DR Jones, J Eckstein, K Ruterbories, ... Drug Metabolism and Disposition 30 (8), 883-891, 2002 | 583 | 2002 |
| The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin JC Gorski, DR Jones, BD Haehner‐Daniels, MA Hamman, EM O'Mara Jr, ... Clinical Pharmacology & Therapeutics 64 (2), 133-143, 1998 | 496 | 1998 |
| Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily JC Gorski, SD Hall, DR Jones, M VandenBranden Biochemical pharmacology 47 (9), 1643-1653, 1994 | 489 | 1994 |
| The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity Z Wang, JC Gorski, MA Hamman, SM Huang, LJ Lesko, SD Hall Clinical Pharmacology & Therapeutics 70 (4), 317-326, 2001 | 486 | 2001 |
| Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, ... Clinical Pharmacology & Therapeutics 97 (3), 247-262, 2015 | 464 | 2015 |
| Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis N Chalasani, CJ Gorski, MS Asghar, A Asghar, B Foresman, SD Hall, ... Hepatology 37 (3), 544-550, 2003 | 439 | 2003 |
| The Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo JC Gorski, SM Huang, A Pinto, MA Hamman, JK Hilligoss, NA Zaheer, ... Clinical Pharmacology & Therapeutics 75 (1), 89-100, 2004 | 402 | 2004 |
| The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants J Zhang, P Kuehl, ED Green, JW Touchman, PB Watkins, A Daly, SD Hall, ... Pharmacogenetics and genomics 11 (7), 555-572, 2001 | 382 | 2001 |
| Accessibility, sustainability, excellence: how to expand access to research publications. Executive summary J Finch, S Bell, L Bellingan, R Campbell, P Donnelly, R Gardner, M Hall, ... International Microbiology 16 (2), 125-132, 2013 | 351 | 2013 |
| Molecular and physical mechanisms of first-pass extraction SD Hall, KE Thummel, PB Watkins, KS Lown, LZ Benet, MF Paine, ... Drug Metabolism and Disposition 27 (2), 161-166, 1999 | 343 | 1999 |
| An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation BS Mayhew, DR Jones, SD Hall Drug Metabolism and Disposition 28 (9), 1031-1037, 2000 | 340 | 2000 |
| The interaction between St John's wort and an oral contraceptive SD Hall, Z Wang, SM Huang, MA Hamman, N Vasavada, AQ Adigun, ... Clinical Pharmacology & Therapeutics 74 (6), 525-535, 2003 | 336 | 2003 |
| The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America SW Grimm, HJ Einolf, SD Hall, K He, HK Lim, KHJ Ling, C Lu, AA Nomeir, ... Drug Metabolism and Disposition 37 (7), 1355-1370, 2009 | 325 | 2009 |
| Mechanism-based inactivation of CYP3A by HIV protease inhibitors CS Ernest, SD Hall, DR Jones Journal of pharmacology and experimental therapeutics 312 (2), 583-591, 2005 | 294 | 2005 |
| Effect of St John's wort on the pharmacokinetics of fexofenadine Z Wang, MA Hamman, SM Huang, LJ Lesko, SD Hall Clinical Pharmacology & Therapeutics 71 (6), 414-420, 2002 | 274 | 2002 |
| Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C MA Hamman, GA Thompson, SD Hall Biochemical pharmacology 54 (1), 33-41, 1997 | 269 | 1997 |
Lang LiThe Ohio State University, College of Medicine在 osumc.edu 的电子邮件经过验证
